| __timestamp | Cytokinetics, Incorporated | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44426000 | 14400000 |
| Thursday, January 1, 2015 | 46398000 | 33800000 |
| Friday, January 1, 2016 | 59897000 | 35900000 |
| Sunday, January 1, 2017 | 90296000 | 1254000 |
| Monday, January 1, 2018 | 89135000 | 4889000 |
| Tuesday, January 1, 2019 | 86125000 | 7400000 |
| Wednesday, January 1, 2020 | 96951000 | 10100000 |
| Friday, January 1, 2021 | 159938000 | 14300000 |
| Saturday, January 1, 2022 | 240813000 | 23200000 |
| Sunday, January 1, 2023 | 330123000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Neurocrine Biosciences, Inc. and Cytokinetics, Incorporated from 2014 to 2023. Over this period, Cytokinetics has seen a staggering increase in its cost of revenue, growing by over 640%, from approximately $44 million in 2014 to $330 million in 2023. In contrast, Neurocrine's cost of revenue has increased by a more modest 176%, from around $1.4 million to $39.7 million in the same timeframe.
This stark difference highlights Cytokinetics' aggressive expansion strategy, while Neurocrine appears to maintain a more controlled cost structure. Understanding these trends provides valuable insights into each company's operational strategies and financial health, offering a glimpse into their future potential in the biotech sector.
Cost of Revenue Comparison: Eli Lilly and Company vs Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: AbbVie Inc. vs Neurocrine Biosciences, Inc.
AstraZeneca PLC vs Cytokinetics, Incorporated: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Pfizer Inc. vs Cytokinetics, Incorporated
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Telix Pharmaceuticals Limited
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.
Neurocrine Biosciences, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Mesoblast Limited
Cost of Revenue Comparison: Incyte Corporation vs Cytokinetics, Incorporated
Cytokinetics, Incorporated vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored